Ritter Pharmaceuticals Initiates Phase 2B/3 Clinical Trial of RP-G28 in Lactose Intolerance
LOS ANGELES, CA -- (Marketwired) -- 03/14/16 -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a leading developer of novel therapeutics that modulate the human gut microbiome to treat …